COMPARISON OF DOXORUBICIN CARDIOTOXICITY IN PEDIATRIC SARCOMA PATIENTS WHEN GIVEN WITH DEXRAZOXANE VERSUS AS CONTINUOUS INFUSION

REFERENCES

• Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol. 1998;25:S72–S85.
   PubMed Web of Science ®Google Scholar
• van Dalen EC, Van Der Pal HJH, Kok WEM, . Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. Eur J Cancer. 2006;42: 3191–3198.
   PubMed Web of Science ®Google Scholar
• Paulides M, Kremers A, Stohr W, . Prospective longitudinal evaluation of doxorubicin-induced cardiomyopathy in sarcoma patients: a report of the Late Effects Surveillance System (LESS). Pediatr Blood Cancer. 2006;46:489–495.
   PubMed Web of Science ®Google Scholar
• Pein F, Sakiroglu O, Dahan M, . Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br J Cancer. 2004;91:37–44.
   PubMed Web of Science ®Google Scholar
• Shapira J, Gotfried M, Lishner M, . Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. Cancer. 1990;65:870–873.
   PubMed Web of Science ®Google Scholar
• Casper ES, Gaynor JJ, Hajdu SI, . A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer. 1991;68:1221–1229.
   PubMed Web of Science ®Google Scholar
• Legha SS, Benjamin RS, Mackay B, . Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982;96:133–139.
   PubMed Web of Science ®Google Scholar
• Berrak SG, Ewer MS, Jaffe N, . Doxorubicin cardiotoxicity in children: reduced incidence of cardiac dysfunction associated with continuous-infusion schedules. Oncol Rep. 2001;8: 611–614.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Giantris AL, Lipsitz SR, . Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91–01 acute lymphoblastic leukemia protocol. J Clin Oncol. 2002;20:1677–1682.
   PubMed Web of Science ®Google Scholar
• Gupta M, Steinherz PG, Cheung NK, . Late cardiotoxicity after bolus versus infusion anthracycline therapy for childhood cancers. Med Pediatr Oncol. 2003;40:343–347.
   PubMedGoogle Scholar
• Iarussi D, Indolfi P, Casale F, . Recent advances in the prevention of anthracycline cardiotoxicity in childhood. Curr Med Chem. 2001;8:1649–1660.
   PubMed Web of Science ®Google Scholar
• Zucchi R, Danesi R. Cardiac toxicity of antineoplastic anthracyclines. Curr Med Chem Anti Cancer Agents. 2003;3:151–171.
   PubMedGoogle Scholar
• Wexler LH, Andrich MP, Venzon D, . Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol. 1996;14:362–372.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Rifai N, Dalton V, . The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med. 2004;351:145–153.
   PubMed Web of Science ®Google Scholar
• Kremer LCM, van Dalen EC, Offringa M, . Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol. 2001;19:191–196.
   PubMed Web of Science ®Google Scholar
• Nysom K, Holm K, Lipsitz SR, . Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol. 1998;16:545–550.
   PubMed Web of Science ®Google Scholar
• Krischer JP, Epstein S, Cuthbertson DD, . Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol. 1997;15: 1544–1552.
   PubMed Web of Science ®Google Scholar
• Elliott P. Pathogenesis of cardiotoxicity induced by anthracyclines. Semin Oncol. 2006;33:S2–S7.
   PubMed Web of Science ®Google Scholar
• Seymour L, Bramwell V, Moran LA. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. Cancer Prev Control. 1999;3:145–159.
   PubMedGoogle Scholar
• Tebbi CK, London WB, Friedman D, . Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol. 2007;25:493–500.
   PubMed Web of Science ®Google Scholar
• van Dalen EC, Caron HN, Dickinson HO, Kremer LCM. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2008;(2):CD003917.
   PubMed Web of Science ®Google Scholar
• Hensley ML, Hagerty KL, Kewalramani T, . American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol. 2009;27:127–145.
   PubMed Web of Science ®Google Scholar
• Adams MJ, Lipsitz SR, Colan SD, . Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol. 2004;22:3139–3148.
   PubMed Web of Science ®Google Scholar
• Van Der Pal HJH, van Dalen EC, Kremer LCM, . Risk of morbidity and mortality from cardiovascular disease following radiotherapy for childhood cancer: a systematic review. Cancer Treat Rev. 2005;31:173–185.
   PubMed Web of Science ®Google Scholar
• Lipshultz SE, Lipsitz SR, Sallan SE, . Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23: 2629–2636.
   PubMed Web of Science ®Google Scholar
• Sorensen K, Levitt GA, Bull C, . Late anthracycline cardiotoxicity after childhood cancer. A prospective longitudinal study. Cancer. 2003;97:1991–1998.
   PubMed Web of Science ®Google Scholar
• Poutanen T, Tikanoja T, Riikonen P, . Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children. J Clin Oncol. 2003;21:2349–2356.
   PubMed Web of Science ®Google Scholar